<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport"
          content="width=device-width, height=device-height, initial-scale=1, maximum-scale=1, user-scalable=0, viewport-fit=cover">
    <title>Ultibro - Una vez al dia - Breezhaler</title>
    <link rel="stylesheet" href="style.css">
</head>
<body>
<div class="container">
    <div class="title-container">
        <div class="title">
            ULTIBRO &reg; Demostrada evidencia integral<br>
            para el tratamiento de la EPOC<sup>1-8</sup>
            <div class="dots">
                <img src="assets/dots_bg.png">
            </div>
            <div class="shadow"></div>
            <div class="bg"></div>
        </div>
    </div>
    <div class="rueda-container">
        <div class="rueda-scroll">
            <div class="rueda">
                <!-- SVG VA AQUI -->
                <?xml version="1.0" encoding="utf-8"?>
                <img src="assets/logo_rueda.png" class="logo_rueda">
                <div class="the-svg">
                    <svg class="svg" version="1.1" id="rueda" xmlns="http://www.w3.org/2000/svg"
                        xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 532.3 531.6"
                        style="enable-background:new 0 0 532.3 531.6;" xml:space="preserve">
                        <path class="st0" d="M364.8,44.8" />
                        <g>
                            <circle class="st1" cx="263.4" cy="263.8" r="242.5" />
                            <circle class="st2" cx="263.4" cy="263.8" r="201.2" />
                            <path class="st3 trigger i-reduccion" d="M494.4,147.7c-47.5,25.4-95.1,50.9-142.7,76.3c-2.8-7.5-8.5-19.6-19.7-31.1c-14.9-15.2-31.4-21.3-39.5-23.7
                		l54.4-151.3c20.8,7.8,52.4,22.5,84.1,50C464.4,96.8,483.8,127.6,494.4,147.7z" />
                            <path class="st4 trigger i-evidencia-cardio" d="M531.7,268.2c-0.4,22.9-3.8,58.2-19.4,97.8c-18.1,46-44.4,77.2-61.4,94.5l-114-118.7
                		c7.2-7.5,17.7-20.3,25.1-38.8c5.4-13.6,7.4-25.9,8.1-34.8H531.7z" />
                            <path class="st5 trigger i-breezhaler" d="M354.1,513.6c-20.5,7-50.7,14.7-87.9,14.7c-40.1,0-72.5-8.9-93.6-16.6c17.8-51.4,35.6-102.7,53.5-154.2
                		c8.7,2.8,22.1,6.1,38.5,5.5c15.3-0.5,27.6-4,36-7.3C318.3,408.4,336.2,461,354.1,513.6z" />
                            <path class="st6 trigger i-calidad-vida" d="M195.9,344.6c-38.3,39.3-76.5,78.6-114.8,118c-17.2-16.9-45.9-49.7-63.8-99.4C3.6,324.8,1.5,290.9,2,268.8
                		h158.2c0,8.7,1.3,24.9,9.8,42.6C178.2,328.4,189.3,339.1,195.9,344.6z" />
                            <path class="st7 trigger i-guias-gold" d="M227.4,171.7c-8.9,4-23.5,11.9-37.2,26.7c-14.2,15.3-21,31.1-24.2,40.4c-51.4-16-102.9-31.8-154.3-47.7
                		c7.2-22.4,23.4-62.9,59.8-101.8c35.5-37.9,73.7-56.7,95.3-65.4C187,73.1,207.2,122.4,227.4,171.7z" />
                            <circle class="st8" cx="266.1" cy="266.8" r="117.3" />
                            <text transform="matrix(0.5532 -0.7099 0.7888 0.6146 89.7922 174.4917)" class="st8 st9 st10">GUÍAS
                                GOLD</text>
                            <text transform="matrix(0.5532 -0.7099 0.7888 0.6146 119.5493 178.2455)" class="st8 st9 st11">2020</text>
                            <text transform="matrix(0.662 0.5332 -0.6273 0.7788 352.395 87.5113)" class="st8 st9 st12">REDUCCIÓN
                                DE</text>
                            <text transform="matrix(0.662 0.5332 -0.6273 0.7788 332.5654 94.6505)"
                                class="st8 st9 st12">EXACERBACIONES</text>
                            <text transform="matrix(0.85 0 0 1 398.0586 311.7236)" class="st8 st9 st13">EVIDENCIA DE</text>
                            <text transform="matrix(0.85 0 0 1 393.4688 329.7236)" class="st8 st9 st13">MEJORÍA DE LA</text>
                            <text transform="matrix(0.85 0 0 1 414.3789 347.7236)" class="st8 st9 st13">FUNCIÓN</text>
                            <text transform="matrix(0.85 0 0 1 382.8438 365.7236)" class="st8 st9 st13">CARDIOVASCULAR</text>
                            <text transform="matrix(0.85 0 0 1 51.6826 336.917)" class="st8 st9 st13">CALIDAD</text>
                            <text transform="matrix(0.85 0 0 1 51.6826 354.917)" class="st8 st9 st13">DE VIDA</text>
                            <text transform="matrix(0.85 0 0 1 217.0981 460.5)" class="st8 st9 st13">BREEZHALER</text>
                            <text transform="matrix(0.8501 0 0 1 304.2256 455.5049)" class="st8 st9 st14">®</text>
                        </g>
                    </svg>
                </div>

                <!-- SVG TERMINA AQUI -->

                <div class="info_st3 info i-reduccion">
                    <img src="assets/info_1.png">
                </div>

                <div class="info_st4 info i-evidencia-cardio">
                    <img src="assets/info_2.png">
                </div>

                <div class="info_st5 info i-breezhaler">
                    <img src="assets/info_3.png">
                </div>

                <div class="info_st6 info i-calidad-vida inv">
                    <img src="assets/info_4.png">
                </div>

                <div class="info_st7 info i-guias-gold inv">
                    <img src="assets/info_5.png">
                </div>

                
            </div>
        </div>
    </div>
    <div class="references">
        <div class="reference ref1">
            <b>LABA:</b> Agonista β2 adrenérgico de acción prolongada <br>
            <b>LAMA:</b> Agonista de los receptores muscarínicos de acción prolongada <br>
            <b>ICS:</b> Corticosteroides inhalados <br>
            <b>pMDI:</b> Inhalador de dosis medida presurizado <br>
        </div>
        <div class="reference ref2">
            <div class="ref_img">
                <img src="assets/ref_logo.png">
            </div>
            <strong>Referencias:</strong><br />
            <strong>1.</strong> Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis,
            management, and prevention of chronic obstructive pulmonary disease. 2020 report.<br />
            <strong>2.</strong> Vogelmeier C, Aalamian-Mattheis M, Greulich T, et al S35 Efficacy and safety of the direct switch
            from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd: the
            crystal study Thorax 2016;71:A22. (1):140.<br />
            <strong>3.</strong> Vogelmeier C, Gaga M, Aalamian-Mattheiset M, Greulichal T, Marin J, Castellani W. et al. Efficacy
            and safety of direct switch to Indacaterol/ glycopyrronium in patients with moderate COPD: the CRYSTAL open-label
            randomised trial. Respir Res. 2017 Jul;18:140.<br />
            <strong>4.</strong> Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G. et al.. The effect of
            indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important
            deterioration in COPD. International journal of chronic obstructive pulmonary disease. 2017 May;12:1325-1337.<br />
            <strong>5.</strong> Frampton JE. QVA 149 IND/GLY (indacaterol/glycopyrronium fixed-dose combination): a review of its
            use in patients with chronic obstructive pulmonary disease. Drugs. 2014 Mar;74(4):465-88.<br />
            <strong>6.</strong> Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT. et al. Indacaterol-Glycopyrronium
            versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 Jun;374(23):2222-34.<br />
            <strong>7.</strong> Hohlfeld, J.M. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular
            filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled,
            single-centre trial. Lancet Respir Med. 2018 May;6(5):368-378.<br />
            <strong>8.</strong> Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive
            pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J.
            2017;49(2).
        </div>
    </div>
</div>
<script src="js/rueda.js"></script>
</body>
</html>
